Skip to content
Novolog, Novorapid(insulin aspart)
Fiasp, NovoMix, NovoRapid, Novolog, Ryzodeg (insulin aspart) is a protein pharmaceutical. Insulin aspart was first approved as Novorapid on 1999-09-07. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Fiasp, Novolog
Combinations
Novolog mix (discontinued: Ryzodeg)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin aspart
Tradename
Proper name
Company
Number
Date
Products
Fiaspinsulin aspartNovo Nordisk Inc.N-208751 RX2017-09-29
3 products
Novologinsulin aspartNovo Nordisk Inc.N-20986 RX2000-06-07
4 products
Show 1 discontinued
Insulin aspart
+
Insulin aspart protamine
Tradename
Proper name
Company
Number
Date
Products
Novolog Mix 70/30insulin aspart protamine and insulin aspartNovo Nordisk Inc.N-21172 RX2001-11-01
2 products
Show 2 discontinued
Insulin aspart
+
Insulin degludec
Tradename
Proper name
Company
Number
Date
Products
Ryzodeg 70/30insulin degludec and insulin aspartNovo Nordisk Inc.N-203313 DISCN2015-09-25
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
fiaspBiologic Licensing Application2019-12-19
novolog mix 70/30Biologic Licensing Application2023-02-04
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10A: Insulins and analogues
A10AB: Insulins and analogues for injection, fast-acting
A10AB05: Insulin aspart
A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
A10AD05: Insulin aspart
A10AD06: Insulin degludec and insulin aspart
HCPCS
No data
Clinical
Clinical Trials
452 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11148617058210
Type 1 diabetes mellitusD003922EFO_0001359E105710503448196
Diabetes mellitusD003920EFO_0000400E08-E132262617
HyperglycemiaD006943HP_0003074R73.9437
HypoglycemiaD007003HP_0001943E16.21123
Gestational diabetesD016640HP_0009800O24.4112
HyperkalemiaD006947HP_0002153E87.511
Coronary artery diseaseD003324I25.111
AtherosclerosisD050197EFO_0003914I25.111
ArteriosclerosisD001161EFO_0009086I7011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E841112
Pregnancy complicationsD01124811
Diabetes complicationsD048909111
AsthmaD001249EFO_0000270J4511
LeukemiaD007938C9511
LymphomaD008223C85.911
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.911
Diabetic neuropathiesD003929EFO_1000783111
Liver cirrhosisD008103EFO_0001422K74.011
PharmacokineticsD010599111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F03212
Cognitive dysfunctionD060825G31.84112
ExerciseD015444EFO_000048311
DeliriumD003693R41.011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients2222
Diabetic retinopathyD003930EFO_000377011
Olfaction disordersD000857R43.011
Taste disordersD01365111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Glucose intoleranceD018149HP_0000833R73.0322
Congenital hyperinsulinismD04490311
Diabetic ketoacidosisD016883EFO_100089711
Chronic renal insufficiencyD051436N1811
Latent autoimmune diabetes in adultsD00007169811
InfectionsD007239EFO_000054411
Insulin resistanceD007333EFO_000261411
Fetal macrosomiaD00532011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINSULIN ASPART
INNinsulin aspart
Description
Insulin aspart
Classification
Protein
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID116094-23-6
RxCUI51428
ChEMBL IDCHEMBL1201496
ChEBI ID
PubChem CID
DrugBankDB01306
UNII IDD933668QVX (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ryzodeg - Novo Nordisk
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Novomix - Novo Nordisk
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Novorapid - Novo Nordisk
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Fiasp - Novo Nordisk
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,920 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,374 adverse events reported
View more details